​
该药物是由总部设在圣地亚哥的生物技术公司Mapp Biopharmaceutical Inc.研发。 公司成立于2003年,根据其官网标语“为预防和治疗传染性疾病研发新型药物,旨在关注全球健康和生物防御”(to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense) 。​